Physician profile
Jiwei Sheng
NPI 1679064075
$7,863.71
in general payments reported to CMS, 2019-2025
20 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 80% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $254 · 2021: $680 · 2022: $1,898 · 2023: $1,304 · 2024: $1,949 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,030 · Travel and Lodging: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,029.70 |
| Travel and Lodging | $720.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,618.09 | 2021-2025 | Tryptyr |
| Ocular Therapeutix, INC. | $896.51 | 2024-2025 | Dextenza |
| Abbvie INC. | $800.97 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $741.58 | 2023-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $695.27 | 2022-2025 | Vabysmo, Susvimo |
| Neurotech Pharmaceuticals, INC. | $446.68 | 2025 | |
| Astellas Pharma US INC | $387.36 | 2024-2025 | Izervay |
| Dutch Ophthalmic, USA | $360.01 | 2023 | Tissueblue, Eva, Combined Machine |
| New World Medical,INC. | $287.13 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $241.56 | 2024-2025 | Syfovre |
| Allergan, INC. | $202.84 | 2019 | |
| Bausch & Lomb Americas INC. | $179.00 | 2024-2025 | Xipere |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.81 | 2019-2021 | |
| Alimera Sciences, INC. | $159.26 | 2023 | Iluvien |
| Johnson & Johnson Surgical Vision, INC. | $147.19 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $137.34 | 2025 | |
| Glaukos Corporation | $132.88 | 2020 | |
| Iridex Corporation | $119.61 | 2021 | |
| Sight Sciences, INC. | $105.88 | 2022 | |
| Mallinckrodt Hospital Products INC. | $39.74 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiwei Sheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.